Evidence map›Paper›PMID 38826329›Full record

ArticlebioRxiv : the preprint server for biology2024

Identification of Druggable Binding Sites and Small Molecules as Modulators of TMC1.

Pedro De-la-Torre, Claudia Martínez-García, Paul Gratias, Matthew Mun, Paula Santana, Nurunisa Akyuz, Wendy González, Artur A Indzhykulian, David Ramírez

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Pedro De-la-TorreDepartment of Otolaryngology - Head and Neck Surgery, Harvard Medical School and Mass Eye and Ear, Boston, MA, USA.ORCID 0000-0002-2434-3345
Claudia Martínez-GarcíaDepartamento de Farmacología, Facultad de Ciencias Biológicas, Universidad de Concepción, Chile.ORCID 0009-0002-0266-3310
Paul GratiasDepartment of Otolaryngology - Head and Neck Surgery, Harvard Medical School and Mass Eye and Ear, Boston, MA, USA.ORCID 0000-0002-5172-2316
Matthew MunDepartment of Otolaryngology - Head and Neck Surgery, Harvard Medical School and Mass Eye and Ear, Boston, MA, USA.ORCID 0000-0002-5471-4813
Paula SantanaFacultad de Ingeniería, Instituto de Ciencias Químicas Aplicadas, Universidad Autónoma de Chile, Santiago, Chile.ORCID 0000-0002-5742-4926
Nurunisa AkyuzDepartment of Neurobiology, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6340-1915
Wendy GonzálezCenter for Bioinformatics and Molecular Simulations (CBSM), University of Talca, Talca 3460000, Chile.ORCID 0000-0002-7535-6883
Artur A IndzhykulianDepartment of Otolaryngology - Head and Neck Surgery, Harvard Medical School and Mass Eye and Ear, Boston, MA, USA.ORCID 0000-0002-2076-6818
David RamírezDepartamento de Farmacología, Facultad de Ciencias Biológicas, Universidad de Concepción, Chile.ORCID 0000-0003-0002-1189

Funding

TRAINING FOR SPEECH AND HEARING SCIENCEST32DC000038 · NIDCD · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Gwenaelle S Geleoc · 1992 to 2026
$21.8M
Molecular Basis of Hair Cell Stereocilia Bundle MorphologyR01DC017166 · NIDCD · MASSACHUSETTS EYE AND EAR INFIRMARY · PI INDZHYKULIAN, ARTUR · 2018 to 2022
$3.5M
Development of Gene Therapy for Hereditary Deafness using Rational Protein EngineeringR01DC020190 · NIDCD · MASSACHUSETTS EYE AND EAR INFIRMARY · PI DAVID P COREY, Artur Indzhykulian · 2022 to 2026
$3.3M
Calcium Regulation in Cochlear CellsR01DC021795 · NIDCD · CASE WESTERN RESERVE UNIVERSITY · PI Artur Indzhykulian, Ruben Stepanyan · 2025 to 2026
$1.3M
NIDCD NIH HHS R01 DC017166NIDCD NIH HHS R01 DC020190NIDCD NIH HHS R01 DC021795NIDCD NIH HHS T32 DC000038
6 · The paper itself

Abstract

Our ability to hear and maintain balance relies on the proper functioning of inner ear sensory hair cells, which translate mechanical stimuli into electrical signals via mechano-electrical transducer (MET) channels, composed of TMC1/2 proteins. However, the therapeutic use of ototoxic drugs, such as aminoglycosides and cisplatin, which can enter hair cells through MET channels, often leads to profound auditory and vestibular dysfunction. Despite extensive research on otoprotective compounds targeting MET channels, our understanding of how small-molecule modulators interact with these channels remains limited, hampering the discovery of novel drugs. Here, we propose a structure-based screening approach, integrating 3D-pharmacophore modeling, molecular dynamics simulations of the TMC1+CIB2+TMIE complex, and experimental validation. Our pipeline successfully identified several novel compounds and FDA-approved drugs that reduced dye uptake in cultured cochlear explants, indicating MET-modulation activity. Simulations, molecular docking and free-energy estimations allowed us to identify three potential drug-binding sites within the channel pore, phospholipids, key amino acids involved in modulator interactions, and TMIE as a flexible component of the MET complex. We also identified shared ligand-binding features between TMC and structurally related TMEM16 proteins, providing novel insights into their distinct inhibition. Our pipeline offers a broad application for discovering modulators for mechanosensitive ion channels.

Identifiers

PMID38826329
PMCPMC11142246

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.